



Stifel Europe Bank AG - Virtual Roadshow Nordics

01 April 2022

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

3


Agenda



Our Purpose and Mission

Ever better medicine for ever more people We improve people's lives by providing high quality and affordable healthcare


A Global Leader in Healthcare Products and Services



Investment Highlights




Global Trends Offer Growth Opportunities for Fresenius



Sources: ¹ UN, Ageing and health (2021) ² UBS, Longer Term Investments: EM healthcare (2018) ³ IDF Diabetes Atlas (2021) ⁴ AAM report (2020) ⁵ UBS, Longer Term Investments: Generics (2018)

The Fresenius Strategy



9

Environment, Social and Governance: Core Priorities



10

Fresenius Group: Significant progress on our ESG agenda



Rating and reporting progress

Rating improvements across the board: CDP Climate at "B", MSCI at "BBB" and Sustainalytics at 17.8 (Low Risk)

EU Taxonomy: 1% revenue, 49% capex, and 0% Opex is **taxonomy-eligible**



Employee engagement

Group-wide survey to be conducted to better understand employees' concerns and demands

Consolidated results expected in Q4/2022



Performance measurement

ESG targets program on track: KPIs defined, **15% of**

Management's short-term

incentive linked to ESG

Strategy and KPI alignment to be **continued in 2022**

KPIs to be included in **new 2023** Long-Term Incentive Plan

Fresenius Group: Climate Targets - our Roadmap to Climate Neutrality in 2040




in line with a science-based 1.5°C scenario Continuous assessment of **scope 3 emission impacts** for inclusion in our targets

First priority: Transition to renewable electricity

12

ESG Rating Overview

Continuous Improvement through Reporting and Engagement




THE USE BY FRESENIUS SE & CO. KGAA OF ANY MSCI ESG RESEARCH LLC OR ITS AFFILIATES ("MSCI") DATA, AND THE USE OF MSCI LOGOS, TRADEMARKS, SERVICE MARKS OR INDEX NAMES HEREIN, DO NOT CONSTITUTE A SPONSORSHIP, ENDORSEMENT, RECOMMENDATION, OR PROMOTION OF FRESENIUS SE & CO. KGAA BY MSCI. MSCI SERVICES AND DATA ARE THE PROPERTY OF MSCI OR ITS INFORMATION PROVIDERS, AND ARE PROVIDED 'AS-IS' AND WITHOUT WARRANTY. MSCI NAMES AND LOGOS ARE TRADEMARKS OR SERVICE MARKS OF MSCI.

Copyright ©2021 Sustainalytics. All rights reserved.


This publication contains information developed by Sustainalytics (<u>www.sustainalytics.com</u>). Such information and data are proprietary of Sustainalytics and/or its third party suppliers (Third Party Data) and are provided for informational purposes only. They do not constitute an endorsement of any product or project, nor an investment advice and are not warranted to be complete, timely, accurate or suitable for a particular purpose. Their use is subject to conditions available at https://www.sustainalytics.com/legal-disclaimers.

Fresenius Group: Global Sales Base in Growing, Non-Cyclical Markets



Before special items 2017-2018 excluding IFRS 16

Fresenius Group: Track Record of Healthy Organic Sales Growth



Fresenius Group: Strong and Balanced Health Care Portfolio





Ownership: ~32%

Health Care Products Health Care Services

- Dialysis services
- Products for hemodialysis and peritoneal dialysis
- Critical care solutions
- Complementary assets to establish holistic treatment approach

Sales 2021: €17.6 bn





Ownership: 100%

Hospital Supplies

- IV drugs
- Clinical nutrition
- Infusion therapy
- Medical devices/ transfusion technology
- Biosimilars

Sales 2021: €7.2 bn

FRESENIUS HELIOS



Ownership: 100%

Hospital Operation

- Acute care
- Outpatient services
- Occupational risk prevention
- Fertility services

Sales 2021: €10.9 bn





Ownership: 77%

Services and Projects for Hospitals

- Post-acute care
- Project development and planning
- Turnkey construction
- Maintenance, technical and total operational management

Sales 2021: €2.3 bn

Fresenius Medical Care: Global Dialysis Market Leader

- The world's leading provider of dialysis products and services treating ~345,000 patients¹ in >4,100 clinics¹
- Provide care and products of highest quality
- Leveraging core competencies to address global Healthcare challenges and further expand in the Renal Care Continuum and beyond
- Advancing global transformation program FME25 to enable further sustainable profitable growth and execution on strategy

ලිළු Health care products

Health care services

Critical care solutions

Complementary assets

Sales by Region



Sales by Products and Services



Market Dynamics

Increase in global demand

>1.6 million p.a.

patients worldwide will need continuous renal replacement therapy to treat acute kidney failure in 2030

Home dialysis

By 2025, the Company aims to perform **25%** of all treatments in the U.S. in a home setting


Digitalization is driving new treatment models

Leverage ever larger data sets from **~53 million** dialysis treatments per year (2021) to further improve and personalize treatments

¹ As of December 31, 2021

Fresenius Kabi: A Leading Global Hospital Supplier

- Comprehensive product portfolio for critically and chronically ill patients
- Leading market positions
- Development of biosimilars with a focus on oncology and autoimmune diseases
- Vision 2026 framework initiated to increase global competitiveness and advance organizational effectiveness



FRESENIUS

Biosimilars

AA

┍═┧╗●

ų

⊈

Fresenius Helios: Europe's Largest Private Hospital Operator

- Market leader in size and quality with excellent growth prospects
- $\sim 6\%^1$ share in German acute care hospital ~12%¹ share in Spanish private hospital market
- Quality is key: defined quality targets, publication of medical treatment results, peer review processes
- Development of new business models to foster digitalization and profit from trend towards outpatient treatments






Market Dynamics Hospital market in Germany ~ €111 bn Downloads of e-health apps in Germany increased in 2020 to 2 million. As a result of the COVID-19 pandemic, they doubles compared to the previous year. Private hospital market in Spain ~ €16 bn Average increase of private health insurance policies in Spain of ~2.5% p.a.

FRESENIUS

Fresenius Vamed: Leading Global Hospital Services and Projects Specialist

- Manages hospital construction/expansion projects and provides services for health care facilities worldwide
- Offers project development, planning, turnkey construction, maintenance as well as technical management, and total operational management
- Strong track record: More than 1,000 projects in 98 countries completed
- Leading post-acute care provider in central Europe



¹ As of December 31, 2021

┨╣╴

¢'

Services

Projects

Post-acute care

Fresenius Group: Medium-term Growth Targets 2020 – 2023 (CAGRs)


FRESENIUS	Organic sales growth 4 - 7%	Bottom to middle of range
	Organic net income ¹ growth 5 - 9%	Bottom of range

Acquisitions have smaller contributions than the $\sim 1\%$ additional growth originally expected

¹ Net income attributable to shareholders of Fresenius SE&Co. KGaA

Before special items

Fresenius SE: Earnings-Linked Dividend Policy




¹ Proposal


² Before special items

56%


Fresenius SE: Fresenius Share & Shareholder Structure



Shareholder structure by investors




Shareholder structure by region



FRESENIUS

Fresenius SE: Historical Share Price Performance




Agenda



Key Messages




Strategic Roadmap: Optimization phase successfully completed – set the stage to create significant value for shareholders and society



Fresenius Group: All Fresenius segments with excellent market positions and ample growth opportunities; access to sufficient capital remains key to accelerate growth

Attractive segments with ample growth opportunities



Attractive for Fresenius to participate in further growth

Extensive growth capital required to capture opportunities across all segments

Fresenius Group: Unlocking value by defining new strategic imperatives to execute on accelerated profitable growth

Advantages of current set-up for our stakeholders

- Diversification and size offer stability, economies of scale and tax savings
- Worldwide presence and brand reputation
- Attractive debt financing conditions


Constraints on accelerating growth

- Extensive growth capital deployment to capture incremental growth opportunities in all segments
- Fresenius financing capacity drives need to prioritize
- Fresenius equity issuance unattractive at current valuation



Fresenius Group: Prioritizing segment capital allocation

and tapping new capital sources



Agenda




Q4/21 Profit and Loss Statement

Sales	EBIT	
+5%	-9%	SUN SUN
Q4/21: €9,966 m	Q4/21: €1,166 m	Net Income
Income Tax Rate	Net Interest	+3%
23.1%	-€120 m	Q4/21: €521 m
Q4/20: 24.1%	Q4/20: -€159 m	

All growth rates in constant currency (cc) Before special items Net income attributable to shareholders of Fresenius SE & Co. KGaA

FRESENIUS

Q4/21 Business Segment Growth



All figures before special items

For a detailed overview of special items please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Q4/21 Cash Flow

Operat	Operating CF		Capex (net)		Free Cash Flow ¹	
Q4/2021	LTM Margin	Q4/2021	LTM Margin	Q4/2021	LTM Margin	
669	14.1%	-268	-4.7%	401	9.4%	
335	16.7%	-170	-7.5%	165	9.2%	
609	11.1%	-226	-5.3%	383	5.8%	
128	6.6%	-22	-3.5%	106	3.1%	
8	n.a.	12	n.a.	20	n.a.	
1,080	13.6%	-406	-6.0%	674	7.6%	
1,749	13.5%	-674	-5.3%	1,075	8.2%	
	Q4/2021 669 335 609 128 8 1,080	Q4/2021 LTM Margin 669 14.1% 335 16.7% 609 11.1% 128 6.6% 8 n.a. 1,080 13.6%	Q4/2021 LTM Margin Q4/2021 669 14.1% -268 335 16.7% -170 609 11.1% -226 128 6.6% -22 8 n.a. 12 1,080 13.6% -406	Q4/2021LTM MarginQ4/2021LTM Margin66914.1%-268-4.7%33516.7%-170-7.5%60911.1%-226-5.3%1286.6%-22-3.5%8n.a.12n.a.1,08013.6%-406-6.0%	Q4/2021 LTM Margin Q4/2021 LTM Margin Q4/2021 669 14.1% -268 -4.7% 401 335 16.7% -170 -7.5% 165 609 11.1% -226 -5.3% 383 128 6.6% -22 -3.5% 106 8 n.a. 12 n.a. 20 1,080 13.6% -406 -6.0% 674	

¹ Before acquisitions and dividends ² Including FMC dividends

Assumptions for Guidance FY/22

Special items are excluded.

Ongoing adverse effects from COVID-19 expected; extent will depend partly on vaccination progress and potential further virus variants.

COVID-19 case numbers expected to decline from spring 2022 onwards; in line with that elective treatments and staff availability are expected to improve.

Guidance does not reflect any potential further containment measures that could have a significant and direct impact on the health care sector without any appropriate compensation.

Headwinds from cost inflation and supply chain challenges are reflected - however no acceleration of effects vs. current environment expected.

FMC's guidance assumptions also apply to FSE guidance.



FY/22 Financial Outlook by Business Segment

€m (except otherwise stated)		FY/21 Base	FY/21	FY/22e
	Sales growth (org)	7,193	4%	Low single-digit %
	EBIT growth (cc)	1,153	7%	Decline in high single- to low double-digit %-range
FRESENIUS HELIOS	Sales growth (org)	10,891	7%	Low-to-mid single-digit %
	EBIT growth (cc)	1,127	10%	Mid single-digit %
	Sales growth (org)	2,297	11%	High single- to low double-digit %
	EBIT growth (cc)	101	248%	Returning to absolute pre- COVID levels (2019: €134 m)

Before special items and including COVID-19 effects

For a detailed overview of special items please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

36


FY/22 Financial Guidance

€m (except otherwise stated)		FY/21 Base	FY/21	FY/22e
F FRESENIUS	Sales growth (cc)	37,520	5%	Mid single-digit %
	Net income growth (cc)	1,867	5%	Low single-digit %

Before special items and including COVID-19 effects Net income attributable to shareholders of Fresenius SE & Co. KGaA

For a detailed overview of special items please see the reconciliation tables provided on our website <u>https://www.fresenius.com/results-center</u>.

Execution of cost & efficiency program in 2022 and 2023 leading to significantly higher savings



Savings target increased to >€150 m p.a after tax and minorities in 2023

¹ After tax and minorities

Agenda





Fresenius Kabi: Headwinds in the U.S. and China as well as macro challenges expected in 2022; transformation program Vision 2026 initiated for continued success



North America

GPO tendering in FY/22

Melrose Park:

- Plant is fully operational
- FDA inspection expected any time
- No product launches from this plant expected in FY/22

>10 product launches planned in FY/22

Asia Pacific

China expected to be marked by significant price pressure post successful participation in NVBP tenders

China remains very attractive market with **significant volume growth potential**

Macro challenges in 2022

Disappearance of COVID related extra **demand**

Significant headwinds from **cost inflation** and **supply chain challenges**


Increased employee fluctuation and absenteeism rate

Vision 2026

Strategy 3+1:

- Broaden biopharmaceutical offering
- Expand in MedTech
- Roll out clinical nutrition
- + Strengthen resilience in **IV business**

Fresenius Kabi: Biosimilars gaining traction, however some product launch delays expected



Update

Adalimumab: FDA accepted submitted aBLA¹ for review; significant progress made to target for launch in important Brazilian market

Pegfilgrastim:

US: FDA approval is pending due to awaited PAI²; committed to supporting the FDA in completing its assessment as soon as possible
EU: positive opinion form CHMP late January 22; expecting market authorization over coming months

Tocilizumab: progresses in line with expectations

Rituximab: Kabi entered into an exclusive license agreement with Dr. Reddy's to commercialize Rituximab in the US; Dr. Reddy's is currently executing clinical trials; FDA submission is expected in 2023

EBITDA break-even with high-triple digit € million sales now expected in 2024

40

Fresenius Helios: Continued progress back to normal operations



Germany

Omicron: decreasing number of COVID patients in ICUs, currently occupying ~10% of ICU capacity

Sequential **admissions increase** in Q4 to continue in 2022, although below pre-pandemic levels

Digital service offerings at

Curalie platform further expanded

Spain

Omicron: peak surpassed; COVID patient numbers currently decreasing occupying <15% of ICU capacity

Excellent contribution from **ORP services** to continue in 2022

Latin American operations on track

Patient portal with ~4.3 million registered users

Fertility Services

2021 sales of €133 million and €19 million EBIT (consol. April 1)

Fertility services in 2021 expanded: **acquisition** of leading reproductive business in the U.S. and CAN; **opening** of new reproductive medicine facility in Vicenza, Italy

Further **bolt-on acquisitions** expected in 2022

External conditions

Stable reimbursement

2022 DRG inflator set at 2.29%

Inflation: increase in energy costs in Germany, personnel & material costs stable; Spain: increase in energy costs and rising personnel costs due to pandemic

Mandatory vaccination in Germany

Fresenius Vamed: Ongoing recovery of business expected; good order intake despite COVID-19



COVID-19 headwinds to ease in the course of 2022

Easing of travel restrictions and quarantine requirements expected

Lack of elective treatments – expected to recover from Spring onwards

Accelerate growth in the post-acute care business

Acquisition of an inpatient rehabilitation clinic to expand into the attractive rehabilitation market in the UK

Recovery of project business in Q4/21 – strong finish to the year

- Sales in project business increased by 62% in Q4/21 over a soft prior year quarter
- Overall order intake in FY/21 increased by 28% versus prior year

Major turnkey contracts in Q4/21:

- Smart Health Posts and App (SMAPP) telemedicine project in Ghana
- Hospital in Öhringen, Germany

Fresenius Kabi: Q4 & FY/21 Organic Sales Growth by Regions

€m	Q4/21	Δ YoY organic	FY/21	Δ YoY organic
North America	589	2%	2,258	-2%
Europe	664	0%	2,544	3%
Emerging Markets	570	-6%	2,391	12%
Total sales	1,823	-1%	7,193	4%

Fresenius Kabi: Q4 & FY/21 Organic Sales Growth by Product Segment

€m	Q4/21	Δ YoY organic	FY/21	Δ YoY organic
IV Drugs	711	-2%	2,816	-2%
Infusion Therapy	237	6%	869	8%
Clinical Nutrition	519	-4%	2,127	10%
Medical Devices/ Transfusion Technology	356	0%	1,381	8%
Total sales	1,823	-1%	7,193	4%

Fresenius Kabi: Q4 & FY/21 EBIT Growth

€m	Q4/21	Δ YoY cc	FY/21	Δ YoY cc
North America	136	1%	637	-16%
Margin	23.1%	+30 bps	28.2%	-480 bps
Europe	64	-26%	374	5%
Margin	9.6%	-290 bps	14.7%	+30 bps
Emerging Markets	199	25%	646	38%
Margin	34.9%	+880 bps	27.0%	+500 bps
Corporate and Corporate R&D	-120	9%	-504	1%
Total EBIT	279	12%	1,153	7%
Margin	15.3%	+230 bps	16.0%	+30 bps

All figures before special items

Margin growth at actual rates

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Fresenius Helios: Q4 & FY/21 Key Financials

€m	Q4/21	∆ YoY cc	FY/21	Δ YoY cc
Total sales	2,882	5% ¹	10,891	7% ¹
Thereof Helios Germany	1,745	4%1	6,733	2%1
Thereof Helios Spain	1,084	9% ¹	4,021	15% ¹
Total EBIT Margin	339 11.8%	3% -60 bps	1,127 10.3%	10% -10 bps
Thereof Helios Germany Margin	171 9.8%	9% +20 bps	613 9.1%	2% -40 bps
Thereof Helios Spain Margin	162 14.9%	3% -100 bps	514 12.8%	24% +70 bps
Thereof Corporate	6		0	

¹ Organic growth

All figures before special items

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Fresenius Helios: Key Metrics

	FY/21	FY/20	Δ
No. of hospitals Germany - Acute care hospitals	90 87	89 86	1% 1%
No. of hospitals Spain (Hospitals)	56	52	8%
No. of beds Germany - Acute care hospitals	30,487 29,955	29,978 29,451	2% 2%
No. of beds Spain (Hospitals)	8,174	7,936	3%
Admissions Germany (acute care)	1,048,946	1,044,959	
Admissions Spain (including outpatients)	17,122,592	15,037,804	

Fresenius Vamed: Q4 & FY/21 Key Financials

€m	Q4/21	Δ YoY cc	FY/21	Δ YoY cc
Total sales Thereof organic sales	748	29% 29%	2,297	11% 11%
Project business	333	62%	717	13%
Service business	415	11%	1,580	10%
Total EBIT ¹	66	69%	101	
Order intake ²	319	-51%	1,290	28%
Order backlog ²			3,473	14%

¹ Before special items ² Project business only

Fresenius Group: Q4/21 Key Financials

€m	Q4/21 ¹	special items	Q4/21 reported	Δ YoY cc ¹
Sales	9,966	-	9,966	5%
EBIT	1,166	-43	1,123	-9%
Net interest	-120	-2	-122	26%
Income taxes	-242	0	-242	10%
Net income ²	521	-22	499	3%

¹ Before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Fresenius Group: FY/21 Key Financials

€m	FY/21 ¹	special items	FY/21 reported	Δ YoY cc ¹
Sales	37,520	-	37,520	5%
EBIT	4,252	-94	4,158	-6%
Net interest	-504	-2	-506	22%
Income taxes	-848	15	-833	6%
Net income ²	1,867	-49	1,818	5%

¹ Before special items

² Net income attributable to shareholders of Fresenius SE & Co. KGaA

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

Fresenius Group: Calculation of Noncontrolling Interests

Net income attributable to Fresenius SE & Co. KGaA	1,867	1,796
Fresenius Helios (- \in 16 m), Fresenius Vamed (- \in 4 m) and due to Fresenius Vamed's 23% external ownership (- \in 15 m)		
Noncontrolling interest holders in Fresenius Kabi (-€58 m),	-93	-55
Noncontrolling interest holders in Fresenius Medical Care	-250	-271
Fresenius Medical Care net income not attributable to Fresenius (Q4/21: ~68%)	-690	-922
Noncontrolling interests, thereof	-1,033	-1,248
Taxes	-848	-914
Earnings before tax and noncontrolling interests	3,748	3,958
€m	FY/21	FY/20

Before special items For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website <u>https://www.fresenius.com/results-center</u>.

Fresenius Group: Cash Flow

€m	Q4/21	LTM Margin	Δ ΥοΥ
Operating Cash Flow	1,749	13.5%	26%
Capex (net)	-674	-5.3%	16%
Free Cash Flow	1,075	8.2%	82%
(before acquisitions and dividends)			
Acquisitions (net)	-157		
Dividends	-77		
Free Cash Flow (after acquisitions and dividends)	841	3.2%	156%

Estimated COVID-19 Effects Q4 & FY/21


	Growt as repo incl. COV	orted	ted COVID-19 in		grow	Estimated growth cc excl. COVID-19		
	Q4/21	Q4/20	Q4/21	Q4/20	Q4/21	Q4/20		
Sales	5%	5%	0% to -1%	-2% to -3%	5% to 6%	7% to 8%		
Net income ¹	3%	2%	0% to -4%	-1% to -5%	3% to 7%	3% to 7%		

	Growth as reporte incl. COVID	orted COVID-19		nated) impact cc	Estimated growth cc excl. COVID-19	
	FY/21	FY/20	FY/21	FY/20	FY/21	FY/20
Sales	5%	5%	0% to -1%	-2% to -3%	5% to 6%	7% to 8%
Net income ¹	5%	-3%	-1% to -5%	-5% to -9%	6% to 10%	2% to 6%

¹Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items

Fresenius Group: Proven Track Record of Deleveraging

Net Debt/EBITDA¹




2002-2019 excluding IFRS 16

¹ At actual FX rates from 2002 to 2010 and at average FX rates from 2011 onwards, for both Net Debt and EBITDA; before special items; pro forma closed acquisitions/divestitures

² Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG

³ Including IFRS 16

Fresenius Group: Major long-term debt maturities¹



¹ As of December 31, 2021, and based on utilization of major financing instruments, excl. Commercial Paper

² Fresenius SE & Co. KGaA EUR 372m Schuldschein & Fresenius Medical Care US Finance II, Inc. USD 700m Bond repaid at maturity on January 31, 2022.


Sales by Business Segment – FX, Acquisitions/Divestitures Effects Q4/21

€m	Q4/21	Q4/20	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisi- tions	Divesti- tures/ Others
Fresenius Medical Care	4,647	4,400	6%	3%	3%	2%	1%	0%
Fresenius Kabi	1,823	1,815	0%	2%	-2%	-1%	0%	-1%
Fresenius Helios	2,882	2,637	9%	0%	9%	5%	4%	0%
Fresenius Vamed	748	577	30%	1%	29%	29%	0%	0%
Total	9,966	9,304	7%	2%	5%	4%	1%	0%

Sales by Business Segment – FX, Acquisitions/Divestitures Effects FY/21

€m	FY/21	FY/20	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisi- tions	Divesti- tures/ Others
Fresenius Medical Care	17,619	17,859	-1%	-3%	2%	1%	1%	0%
Fresenius Kabi	7,193	6,976	3%	-1%	4%	4%	0%	0%
Fresenius Helios	10,891	9,818	11%	0%	11%	7%	4%	0%
Fresenius Vamed	2,297	2,068	11%	0%	11%	11%	0%	0%
Total	37,520	36,277	3%	-2%	5%	4%	1%	0%

Fresenius Group: Solid Balance Sheet Structure



- Healthy Equity and Liability Split
- Strong equity ratio of >40% on average
- Equity ratio kept in narrow range despite rapid growth of Fresenius Group

Fresenius Group: Financial Performance Indicators

Growth	Profitability	Liqudity	Capital efficiency	Capital management
Sales growth (in constant currency) Sales growth (organic)	<pre>Operating income (EBIT) +/ - Financial result - Income taxes - Minority interests = Net income EBIT growth (in constant currency) Net income growth (in constant currency)</pre>	Operating cash flow ÷ Sales = Cash flow margin	EBIT Income taxes = NOPAT ÷ Invested capital = ROIC EBIT ÷ Operating assets = ROOA	Net debt ÷ EBITDA = Leverage ratio

Fresenius Group¹: Performance Indicators 5-year Overview

	Targets 2021 ²	2021	2020	2019	2018	2017
Sales growth (in constant currency)	Mid single-digit %	5%	5%	6%	6%	16%
Net income ³ growth (in constant currency)	Around top-end of low single-digit %	5%	-3%	0%	7%	21%
Liquidity and capital management						
Cash flow margin	10% to 12%	13.5%	18.1%	12.0%/9.9% ⁴	11.2%	11.6%
Net debt / EBITDA ⁵	Around the top-end of 3.0x - 3.5x ⁶	3.51x	3.44x	3.61x/ 3.14x ⁴	2.71x	2.84x
Capital efficiency						
Return on invested capital (ROIC) ⁷	Decrease by 50 to 100 basis points compared to 2020 level	5.9%	6.5%	6.7%/7.4% ⁴	8.3%	8.0%
Return on operating assets (ROOA) ⁷	Decrease by 40 to 70 basis points compared to 2020 level	6.5%	7.3%	7.6%/8.2%4	9.0%	9.4%

¹ Growth rates are based on the assumptions of the respective annual forecasts and are adjusted for special items and, if applicable, other effects affecting the underlying growth

(adjustments to new accounting standards, acquisitions / divestments, acquisition costs, or cost-saving programs). ² Including estimated COVID-19 effects (updated November 2021)

³ Net income attributable to shareholders of Fresenius SE & Co. KGaA

⁴ Excluding IFRS 16 effect

⁵ Both net debt and EBITDA calculated at LTM average exchange rates; before special items, pro forma closed acquisitions/divestitures

⁶ Around the top-end of the self-imposed target range of 3.0x to 3.5x; excluding further potential acquisitions

⁷ Before special items, pro forma acquisitions

Business segments¹: Performance Indicators 5-year Overview

	Targets 2021 ²	2021	2020	2019	2018	2017
Fresenius Medical Care				2019	2010	
Sales growth (in constant currency)	Expecting to be at the lower end of the guidance range of low-to-mid single-digit %	2%	5%	5%	4%	9%
Net income growth ^{3,4} (in constant currency)	Expecting to be at the lower end of the guidance range of high-teens to mid-twenties %- decline	-23%	12%	-2%	4%	7%
Fresenius Kabi						
Sales growth (organic)	Low-to-mid single-digit %	4%	4%	4%	7%	7%
EBIT growth (in constant currency)	Around the top end of the low single-digit %-guidance range	7%	-6%	3%	2%	8%
Fresenius Helios						
Sales growth (organic)	Mid single-digit percentage growth	7%	4%	5%	3%	4%
EBIT growth (in constant currency)	High single-digit percentage growth	10%	0%	-4%	0%	54%
Fresenius Vamed						
Sales growth (organic)	Mid-to-high single-digit %	11%	-8%	16%	16%	6%
EBIT growth (in constant currency)	High double-digit € million amount	€101 million	€29 million	19%	45%	10%

¹ Growth rates are based on the assumptions of the respective annual forecasts and are adjusted for special items and, if applicable,

other effects affecting the underlying growth (adjustments to new accounting standards, acquisitions / divestments, acquisition costs, or cost-saving programs). ² Including estimated COVID-19 effects (updated November 2021)

³ Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

⁴ Special items are effects (when consolidated at the Fresenius Group: special items), that are unusual in nature and were not foreseeable or not foreseeable in size or impact at the time of giving guidance.

Financial Calendar / Contact



Financial Calendar

04 May 2022	Results Q1/22
13 May 2022	Annual General Meeting
02 August 2022	Results Q2/22
01 November 2022	Results Q3/22

Contact

Investor Relations & Sustainability Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e-mail: ir-fre@fresenius.com

For further information and current news: www.fresenius.com



lin

www.twitter.com/fresenius_ir

www.linkedin.com/company/fresenius-investor-relations

Please note that these dates could be subject to change.

